Benevolent news
London, 3 February 2022, BenevolentAI, a leading clinical-stage AI-drug discovery company, today announced details of an AI research collaboration with the Helix Group, a Stanford University-based research lab led by Professor Russ Altman. The partnership aims to discover more effective methods to extract knowledge from biological and clinical information and ultimately extend the potential of artificial intelligence in helping scientists discover and develop better medi
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids.
BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able
Two novel targets identified through the existing collaboration have already been added to AstraZeneca’s portfolio
London, 13 January 2021, BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes an upfront payment, research funding, development milestone p
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT.
About BenevolentAI
BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabi
- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca
- Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021
London, 15 December 2021: BenevolentAI, a leading clinical-stage AI drug discovery company, announce